Allos buy could be silver lining for Spectrum after cancer drug setback
This article was originally published in Scrip
Executive Summary
In the midst of facing new problems with one its investigational late-stage anticancer agents, Spectrum Pharmaceuticals has set its sights on acquiring Allos Therapeutics for up to $206 million – eyeing that firm’s FDA-approved peripheral T-cell lymphoma (PTCL) medicine Folotyn (pralatrexate injection).